Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.60 |
| ▸ | AGXT | P21549 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 12/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 4/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.44 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767187 | 0.87 | IDO1 (0.69) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL9347048 | 0.83 | IDO1 (0.64) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL31568444 | 0.82 | TSHR (0.62) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL22469745 | 0.82 | TSHR (0.62) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL6291712 | 0.82 | IDO1 (0.62) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL30487709 | 0.80 | IDO1 (0.60) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL8132483 | 0.80 | IDO1 (0.60) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL11019425 | 0.80 | IDO1 (0.60) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL9134590 | 0.79 | IDO1 (0.55) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL514759 | 0.79 | IDO1 (0.64) | IDO1AGXTMAOBTAAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| CN-101516878-A | Thiadiazole compound and use thereof | SUMITOMO CHEMICAL CO (JP) | 2009-08-26 | — | — | CN | disclosed |
| EP-2061789-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008032858-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | IDO1 1716/4885AGXT 3155/4885MAOB 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.